Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL356695 | 0.91 | CHRM2 (0.72) | CHRM2CHRM3 | |
| SCHEMBL266141 | 0.90 | CHRM2 (0.69) | CHRM2CHRM3 | |
| SCHEMBL265681 | 0.88 | CHRM2 (0.62) | CHRM2CHRM3 | |
| SCHEMBL381835 | 0.86 | CHRM2 (0.66) | CHRM2CHRM3 | |
| SCHEMBL644727 | 0.86 | CHRM2 (0.58) | CHRM2CHRM3 | |
| SCHEMBL266994 | 0.85 | CHRM2 (0.61) | CHRM2CHRM3 | |
| SCHEMBL10015120 | 0.85 | CHRM2 (0.71) | CHRM2CHRM3 | |
| SCHEMBL266337 | 0.85 | CHRM3 (0.60) | CHRM3 | |
| SCHEMBL265710 | 0.85 | CHRM2 (0.60) | CHRM2CHRM3 | |
| SCHEMBL265736 | 0.85 | CHRM2 (0.60) | CHRM2CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130274288-A1 | BIPHENYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | THERAVANCE, INC. (US) | 2013-10-17 | — | — | US | disclosed |
| US-20130274288-A1 | BIPHENYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | THERAVANCE, INC. (US) | 2013-10-17 | — | — | US | disclosed |
| US-8487107-B2 | Biphenyl compounds useful as muscarinic receptor antagonists | THERAVANCE, INC. (US) | 2013-07-16 | — | — | US | disclosed |
| US-8487107-B2 | Biphenyl compounds useful as muscarinic receptor antagonists | THERAVANCE, INC. (US) | 2013-07-16 | — | — | US | disclosed |
| US-8487107-B2 | Biphenyl compounds useful as muscarinic receptor antagonists | THERAVANCE, INC. (US) | 2013-07-16 | — | — | US | disclosed |
| US-8476253-B2 | Amide derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-07-02 | — | — | US | disclosed |
| US-8377966-B2 | Biphenyl compounds useful as muscarinic receptor antagonists | THERAVANCE, INC. (US) | 2013-02-19 | — | — | US | disclosed |
| US-8377966-B2 | Biphenyl compounds useful as muscarinic receptor antagonists | THERAVANCE, INC. (US) | 2013-02-19 | — | — | US | disclosed |
| US-20120122926-A1 | BIPHENYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | THERAVANCE, INC. (US) | 2012-05-17 | — | — | US | disclosed |
| US-20120122926-A1 | BIPHENYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | THERAVANCE, INC. (US) | 2012-05-17 | — | — | US | disclosed |
| US-20080058374-A1 | Crystalline forms of a biphenyl compound | THERAVANCE BIOPHARMA R&D IP, LLC | 2008-03-06 | — | — | US | disclosed |
| US-20080058374-A1 | Crystalline forms of a biphenyl compound | THERAVANCE BIOPHARMA R&D IP, LLC | 2008-03-06 | — | — | US | disclosed |
| US-20080058374-A1 | Crystalline forms of a biphenyl compound | THERAVANCE BIOPHARMA R&D IP, LLC | 2008-03-06 | — | — | US | disclosed |
| EP-1856048-A1 | BIPHENYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | Theravance, Inc. (US) | 2007-11-21 | — | — | EP | disclosed |
| WO-2006098999-A1 | BIPHENYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | THERAVANCE, INC. (US) | 2006-09-21 | — | — | WO | disclosed |
| WO-2006098997-A1 | BIPHENYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | THERAVANCE, INC. (US) | 2006-09-21 | — | — | WO | disclosed |
| WO-2006099091-A1 | BIPHENYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | THERAVANCE, INC. (US) | 2006-09-21 | — | — | WO | disclosed |
| US-20060205784-A1 | Biphenyl compounds useful as muscarinic receptor antagonists | THERAVANCE, INC. | 2006-09-14 | — | — | US | disclosed |
| US-20060205778-A1 | Biphenyl compounds useful as muscarinic receptor antagonists | THERAVANCE, INC. | 2006-09-14 | — | — | US | disclosed |
| US-20060205777-A1 | Biphenyl compounds useful as muscarinic receptor antagonists | THERAVANCE, INC. | 2006-09-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060205778-A1 | Biphenyl compounds useful as muscarinic receptor antagonists | CHRM2, CHRM1, CHRM3 | CHRM2 1/4885CHRM3 3/4885 |
| US-20060205784-A1 | Biphenyl compounds useful as muscarinic receptor antagonists | CHRM2, CHRM1, CHRM3 | CHRM2 1/4885CHRM3 3/4885 |
| US-20060205777-A1 | Biphenyl compounds useful as muscarinic receptor antagonists | CHRM2, CHRM1, CHRM3 | CHRM2 1/4885CHRM3 3/4885 |
| US-20130274288-A1 | BIPHENYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | CHRM2, CHRM1, CHRM3 | CHRM2 1/4885CHRM3 3/4885 |
| US-20080058374-A1 | Crystalline forms of a biphenyl compound | ADH1C, ALK, CYP26B1 | CHRM2 754/4885CHRM3 549/4885 |
| US-20120122926-A1 | BIPHENYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | CHRM2, CHRM1, CHRM3 | CHRM2 1/4885CHRM3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.